Tardive Dyskinesia Across Psychiatric Disorders

Download All
Access these interactive, online programs designed to provide the care team with the resources and practical guidance they need to apply the most recent data, guidelines, and expert recommendations for the personalized treatment of their patients with tardive dyskinesia.
Leslie Citrome, MD, MPH
Rif S. El-Mallakh, MD
Joseph F. Goldberg, MD
Sanjay Gupta, MD
W. Clay Jackson, MD, DipTh
Manish Jha, MD
John M. Kane, MD
Greg Mattingly, MD
Joseph P. McEvoy, MD
Roger McIntyre, MD, FRCPC
Jonathan M. Meyer, MD
person default
Diana O. Perkins, MD, MPH
Rebecca S. Roma, MD
person default
Martha Sajatovic, MD

Podcasts

Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).

Joseph F. Goldberg, MD Roger McIntyre, MD, FRCPC Released: May 24, 2021

Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.

Leslie Citrome, MD, MPH Joseph P. McEvoy, MD Released: June 11, 2021

John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.

John M. Kane, MD Rebecca S. Roma, MD Released: July 20, 2021

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.

W. Clay Jackson, MD, DipTh Greg Mattingly, MD Released: August 20, 2021

Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss a multidisciplinary approach to the evaluation and treatment of patients with tardive dyskinesia.

W. Clay Jackson, MD, DipTh Greg Mattingly, MD Released: November 16, 2021

Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the functional and social impact of tardive dyskinesia on the lives of patients.

 

person default Diana O. Perkins, MD, MPH person default Martha Sajatovic, MD Released: January 11, 2022

ClinicalThought

The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.

Joseph P. McEvoy, MD Released: May 4, 2021

Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.

Rif S. El-Mallakh, MD Released: June 8, 2021

Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.

Jonathan M. Meyer, MD Released: July 8, 2021

Tardive dyskinesia (TD) has a real-world impact on patient lives. Greg Mattingly, MD, explores the social and emotional impact of TD on patients as well as its prevalence and diagnosis.

Greg Mattingly, MD Released: September 27, 2021

The availability of 2 FDA-approved agents for the treatment of tardive dyskinesia has been a tremendous accomplishment. In this ClinicalThought, I explore the choices of FDA-approved agents to treat tardive dyskinesia and review what to consider.

Sanjay Gupta, MD Released: November 19, 2021

The burden of schizophrenia and tardive dyskinesia is extensive. In this expert commentary, Martha Sajatovic, MD, explores the American Psychiatric Association 2021 practice guidelines on tardive dyskinesia management in schizophrenia and the advancements in pharmacologic and psychosocial treatments.

person default Martha Sajatovic, MD Released: February 7, 2022

Downloadable Slidesets

Formulate an approach to select the right treatment for patients with tardive dyskinesia.

Manish Jha, MD Released: June 17, 2021

Formulate an approach to diagnose patients with tardive dyskinesia.

Greg Mattingly, MD Released: June 21, 2021

Interactive Case Challenge

This eCase explores diagnosis and treatment of tardive dyskinesia in an older female patient with a history of bipolar disorder.

Rebecca S. Roma, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

This eCase explores diagnosis and treatment of tardive dyskinesia in a male patient with schizophrenia.

John M. Kane, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category 1 CME credits Released: November 3, 2021 Expired: November 2, 2022

This eCase explores the diagnosis and treatment of tardive dyskinesia in a female patient with a long history of bipolar disorder.

Greg Mattingly, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credit Released: February 28, 2022 Expired: February 27, 2023

This eCase explores diagnosis, treatment, and impact of tardive dyskinesia in patients with mood disorders.

Joseph P. McEvoy, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credit Released: February 28, 2022 Expired: February 27, 2023

Journal Article

In the journal supplement to Current Psychiatry, diagnostic dilemmas and choosing the right treatment in patients with tardive dyskinesia (TD) were covered by Manish Jha, MBBS and Greg Mattingly, MD. These articles covered an overview of TD, identification of traditional treatment approaches to TD and their limitations, and details from recent research relating to the efficacy and safety of novel treatment options for TD.

To complete the evaluation and claim credit, please click “Begin Activity” at left and then “Claim Credit” on the next screen.

Manish Jha, MD Greg Mattingly, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Physician Assistants: maximum of 0.5 hours of AAPA Category I (Preapproved) credits Released: October 29, 2021 Expired: October 31, 2022

Neuroscience Research Review: Tardive Dyskinesia Issue 113, September 2021

Two expert faculty members discuss key articles in tardive dyskinesia research and the clinical implications, strengths, limitations, and salient conclusions.

Sanjay Gupta, MD Joseph P. McEvoy, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

On-Demand Webcast

In this interactive recording of a live CCO webinar, Greg Mattingly, MD, and Manish Jha, MBBS, discuss diagnostic dilemmas with tardive dyskinesia, as well as choosing the right treatment.

Manish Jha, MD Greg Mattingly, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Physician Assistants: maximum of 1.5 hours of AAPA Category I CME credits Psychologists: 1.5 APA CE Credits Social Workers: 1.5 ACE CE Credits Released: October 22, 2021 Expired: October 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings